Earlier industry involvement in repurposing activities and a more tailored European regulatory environment for value added medicines are among the proposals set out in a new report published by Medicines for Europe. The association has also suggested creating an “indications pool” to act as a central repository for repurposing information generated by not-for-profit and academic organizations through a STAMP pilot project.
Multiple proposals aimed at realizing the “untapped potential” of repurposing European generics have been set out in a new report by off-patent industry association Medicines for Europe.
In its report, “Advancing Medicines Repurposing In The EU,” the association urges earlier industry involvement in repurposing activities, as well a more tailored European regulatory environment for value added...